530 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Autor: Hassoun, Hani, Jacobus, Susanna J, Richardson, Paul G., Zonder, Jeffrey, Voorhees, Peter M., Kaufman, Jonathan L., Yee, Andrew J, Scott, Emma C, Torka, Pallawi, Libby, Edward N., Reeves, Brandi, Wang, Michael L., Anderson, Larry D., Jr., Milner, Carter, Gasparetto, Cristina, Agha, Mounzer, Khan, Dr. Abdullah, Hurd, David D, Avigan, David E., Costello, Caitlin, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S, Medvedova, Eva, McCarthy, Dr. Philip L., Orlowski, Robert Z., Nadeem, Omar, Laubach, Jacob, Pasquini, Marcelo, Giralt, Sergio, Masone, Kelly, Samur, Mehmet, Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Weller, Edie, Munshi, Nikhil C., Anderson, Kenneth C.
Zdroj: In Transplantation and Cellular Therapy February 2023 29(2) Supplement:S396-S397
Databáze: ScienceDirect
Externí odkaz: